Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity.
Read Article
A current review article addressed the management of gout patients with chronic kidney disease (CKD). This full read review addresses the epidemiology, challenges, treatment decisions and outcomes.
Read Article
Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers.
Read Article
In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1).
Read Article
I recently attended a fascinating lecture by Dr. Anisha Dua on progress in the diagnosis and treatment of large-vessel vasculitis, with a focus on giant cell arteritis (GCA) and Takayasu's arteritis.
Read Article
I recently attended a talk at RWCS by Dr. Gina Woods from UC San Diego on osteoporosis. As rheumatologists, most of us manage osteoporosis in some form every single day. If there is one constant in this space, it’s that osteoporosis care keeps evolving.
Read Article
An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost effectiveness and clinical utility of early BEL initiation in active lupus patients.
Read Article
Today the FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older (who weigh at least 40 kg) who are candidates for systemic therapy or phototherapy, according to a
Read Article
With increasing demand for health services in an aging population, serving complex patients with comorbidities, and increasing healthcare costs, the question of whether nurses can substitute for physicians was addressed by a recent Cochrane review.
In rheumatoid arthritis (RA), the goal is to control or arrest inflammation such that articular and bony damage is halted.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
